{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:21:22Z","timestamp":1790310082135,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T00:00:00Z","timestamp":1590105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T00:00:00Z","timestamp":1590105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s00228-020-02897-x","type":"journal-article","created":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T04:02:45Z","timestamp":1590120165000},"page":"1183-1191","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Factors affecting high-grade hepatotoxicity of tyrosine kinase inhibitors in cancer patients: a multi-center observational study"],"prefix":"10.1007","volume":"76","author":[{"given":"Ji Min","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Won","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Kyoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Young","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soyeon","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dasom","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon Sook","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inyoung","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Youn","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0278-2563","authenticated-orcid":false,"given":"Hye Sun","family":"Gwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,22]]},"reference":[{"issue":"2","key":"2897_CR1","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1056\/NEJMra044389","volume":"353","author":"DS Krause","year":"2005","unstructured":"Krause DS, Van Etten RA (2005) Tyrosine kinases as targets for cancer therapy. N Engl J Med 353(2):172\u2013187","journal-title":"N Engl J Med"},{"issue":"1","key":"2897_CR2","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1161\/CIRCULATIONAHA.108.776831","volume":"118","author":"MH Chen","year":"2008","unstructured":"Chen MH, Kerkel\u00e4 R, Force T (2008) Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation 118(1):84\u201395","journal-title":"Circulation"},{"key":"2897_CR3","first-page":"357027","volume":"2014","author":"N Iqbal","year":"2014","unstructured":"Iqbal N, Iqbal N (2014) Imatinib: a breakthrough of targeted therapy in cancer. Chemother Res Pract 2014:357027","journal-title":"Chemother Res Pract"},{"issue":"5","key":"2897_CR4","first-page":"935","volume":"8","author":"MH Cohen","year":"2002","unstructured":"Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A, Benson K, Leighton J, Kim SK, Wood R, Rothmann M, Chen G, U K, Staten AM, Pazdur R (2002) Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 8(5):935\u2013942","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2897_CR5","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s40264-013-0047-5","volume":"36","author":"RR Shah","year":"2013","unstructured":"Shah RR, Morganroth J, Shah DR (2013) Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval). Drug Saf 36(5):295\u2013316","journal-title":"Drug Saf"},{"issue":"6","key":"2897_CR6","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s40264-013-0050-x","volume":"36","author":"DR Shah","year":"2013","unstructured":"Shah DR, Shah RR, Morganroth J (2013) Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy. Drug Saf 36(6):413\u2013426","journal-title":"Drug Saf"},{"issue":"2","key":"2897_CR7","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.critrevonc.2010.11.007","volume":"80","author":"FA Schutz","year":"2011","unstructured":"Schutz FA, Je Y, Choueiri TK (2011) Hematologic toxicities in cancer patients treated with the multi-tyrosine kinase sorafenib: a meta-analysis of clinical trials. Crit Rev Oncol Hematol 80(2):291\u2013300","journal-title":"Crit Rev Oncol Hematol"},{"issue":"7","key":"2897_CR8","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s40264-013-0048-4","volume":"36","author":"RR Shah","year":"2013","unstructured":"Shah RR, Morganroth J, Shah DR (2013) Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives. Drug Saf 36(7):491\u2013503","journal-title":"Drug Saf"},{"key":"2897_CR9","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3389\/fphar.2017.00367","volume":"8","author":"F Paech","year":"2017","unstructured":"Paech F, Bouitbir J, Kr\u00e4henb\u00fchl S (2017) Hepatocellular toxicity associated with tyrosine kinase inhibitors: mitochondrial damage and inhibition of glycolysis. Front Pharmacol 8:367","journal-title":"Front Pharmacol"},{"issue":"1","key":"2897_CR10","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1186\/s12885-018-4891-7","volume":"18","author":"MK Kim","year":"2018","unstructured":"Kim MK, Yee J, Cho YS, Jang HW, Han JM, Gwak HS (2018) Risk factors for erlotinib-induced hepatotoxicity: a retrospective follow-up study. BMC Cancer 18(1):988","journal-title":"BMC Cancer"},{"issue":"2","key":"2897_CR11","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/jcph.1010","volume":"58","author":"S Cho","year":"2018","unstructured":"Cho S, Yee J, Kim JY, Jeong Rhie S, Gwak HS (2018) Effects of concomitant medication use on Gefitinib-induced hepatotoxicity. J Clin Pharmacol 58(2):263\u2013268","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"2897_CR12","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1097\/CAD.0000000000000622","volume":"29","author":"YH Park","year":"2018","unstructured":"Park YH, Cho S, Yee J, Kim JY, Rhie SJ, Gwak HS (2018) Factors affecting time to reach and recover from gefitinib-induced hepatotoxicity. Anti-Cancer Drugs 29(5):471\u2013476","journal-title":"Anti-Cancer Drugs"},{"issue":"12","key":"2897_CR13","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1007\/s12032-018-1213-5","volume":"35","author":"D Jung","year":"2018","unstructured":"Jung D, Han JM, Yee J, Kim JY, Gwak HS (2018) Factors affecting crizotinib-induced hepatotoxicity in non-small cell lung cancer patients. Med Oncol 35(12):154","journal-title":"Med Oncol"},{"key":"2897_CR14","unstructured":"Common terminology criteria for adverse events (CTCAE): version 4.0 (2010) National Cancer Institute Enterprise vocabulary services website. National Cancer Institute"},{"issue":"10","key":"2897_CR15","doi-asserted-by":"publisher","first-page":"djv216","DOI":"10.1093\/jnci\/djv216","volume":"107","author":"G Thanarajasingam","year":"2015","unstructured":"Thanarajasingam G, Hubbard JM, Sloan JA, Grothey A (2015) The imperative for a new approach to toxicity analysis in oncology clinical trials. J Natl Cancer Inst 107(10):djv216","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"2897_CR16","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1182\/blood-2013-03-492835","volume":"122","author":"JR Veatch","year":"2013","unstructured":"Veatch JR, Sandhu V, Becker PS, Pagel JM, Appelbaum FR, Estey E (2013) The NCI common toxicity criteria and treatment-associated mortality in acute myeloid leukemia. Blood 122(2):293\u2013294","journal-title":"Blood"},{"issue":"1","key":"2897_CR17","doi-asserted-by":"publisher","first-page":"181","DOI":"10.4143\/crt.2019.131","volume":"52","author":"JM Han","year":"2019","unstructured":"Han JM, Yee J, Cho YS, Gwak HS (2019) Factors influencing imatinib-induced hepatotoxicity. Cancer Res Treat 52(1):181\u2013188","journal-title":"Cancer Res Treat"},{"issue":"1","key":"2897_CR18","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s10549-019-05382-x","volume":"178","author":"JY Moon","year":"2019","unstructured":"Moon JY, Han JM, Seo I, Gwak HS (2019) Risk factors associated with the incidence and time to onset of lapatinib-induced hepatotoxicity. Breast Cancer Res Treat 178(1):239\u2013244","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"2897_CR19","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1634\/theoncologist.6-2-162","volume":"6","author":"PD King","year":"2001","unstructured":"King PD, Perry MC (2001) Hepatotoxicity of chemotherapy. Oncologist 6(2):162\u2013176","journal-title":"Oncologist"},{"issue":"3","key":"2897_CR20","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1097\/FPC.0b013e3283385a1c","volume":"21","author":"LM Hodges","year":"2011","unstructured":"Hodges LM, Markova SM, Chinn LW, Gow JM, Kroetz DL, Klein TE, Altman RB (2011) Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenet Genomics 21(3):152\u2013161","journal-title":"Pharmacogenet Genomics"},{"issue":"2","key":"2897_CR21","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/clpt.2012.73","volume":"92","author":"NR Budha","year":"2012","unstructured":"Budha NR, Frymoyer A, Smelick GS, Jin JY, Yago MR, Dresser MJ, Holden SN, Benet LZ, Ware JA (2012) Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy? Clin Pharmacol Ther 92(2):203\u2013213","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"2897_CR22","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1517\/17425255.2010.506873","volume":"6","author":"DR Duckett","year":"2010","unstructured":"Duckett DR, Cameron MD (2010) Metabolism considerations for kinase inhibitors in cancer treatment. Expert Opin Drug Metab Toxicol 6(10):1175\u20131193","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"4","key":"2897_CR23","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/j.1365-2125.2009.03370.x","volume":"67","author":"DA Smith","year":"2009","unstructured":"Smith DA, Koch KM, Arya N, Bowen CJ, Herendeen JM, Beelen A (2009) Effects of ketoconazole and carbamazepine on lapatinib pharmacokinetics in healthy subjects. Br J Clin Pharmacol 67(4):421\u2013426","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"2897_CR24","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s00280-003-0722-9","volume":"53","author":"AE Bolton","year":"2004","unstructured":"Bolton AE, Peng B, Hubert M, Krebs-Brown A, Capdeville R, Keller U, Seiberling M (2004) Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. Cancer Chemother Pharmacol 53(2):102\u2013106","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"2897_CR25","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1177\/0192623309351719","volume":"38","author":"JR Senior","year":"2010","unstructured":"Senior JR (2010) Unintended hepatic adverse events associated with cancer chemotherapy. Toxicol Pathol 38(1):142\u2013147","journal-title":"Toxicol Pathol"},{"key":"2897_CR26","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/978-3-642-00663-0_7","volume":"196","author":"A Srivastava","year":"2010","unstructured":"Srivastava A, Maggs JL, Antoine DJ, Williams DP, Smith DA, Park BK (2010) Role of reactive metabolites in drug-induced hepatotoxicity. Handb Exp Pharmacol 196:165\u2013194","journal-title":"Handb Exp Pharmacol"},{"issue":"2","key":"2897_CR27","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s10549-012-1995-7","volume":"133","author":"YL Teo","year":"2012","unstructured":"Teo YL, Saetaew M, Chanthawong S, Yap YS, Chan EC, Ho HK et al (2012) Effect of CYP3A4 inducer dexamethasone on hepatotoxicity of lapatinib: clinical and in vitro evidence. Breast Cancer Res Treat 133(2):703\u2013711","journal-title":"Breast Cancer Res Treat"},{"issue":"25","key":"2897_CR28","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","volume":"362","author":"M Maemondo","year":"2010","unstructured":"Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T (2010) Gefitinib or chemotherapy for non\u2013small-cell lung cancer with mutated EGFR. N Engl J Med 362(25):2380\u20132388","journal-title":"N Engl J Med"},{"issue":"10","key":"2897_CR29","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1200\/JCO.2011.36.8456","volume":"30","author":"JY Han","year":"2012","unstructured":"Han JY, Park K, Kim SW, Lee DH, Kim HY, Kim HT, Ahn MJ, Yun T, Ahn JS, Suh C, Lee JS, Yoon SJ, Han JH, Lee JW, Jo SJ, Lee JS (2012) First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol 30(10):1122\u20131128","journal-title":"J Clin Oncol"},{"issue":"13","key":"2897_CR30","doi-asserted-by":"publisher","first-page":"3908","DOI":"10.1158\/1078-0432.CCR-06-0462","volume":"12","author":"DM Jackman","year":"2006","unstructured":"Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, Joshi VA, Bell DW, Huberman MS, Halmos B, Rabin MS, Haber DA, Lynch TJ, Meyerson M, Johnson BE, J\u00e4nne PA (2006) Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 12(13):3908\u20133914","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2897_CR31","first-page":"325","volume":"17","author":"Y Ma","year":"2017","unstructured":"Ma Y, Xin S, Huang M, Yang Y, Zhu C, Zhao H, Zhang Y, Chen L, Zhao Y, Li J, Zhuang W, Zhu X, Zhang L, Wang X (2017) Determinants of Gefitinib toxicity in advanced non-small cell lung cancer (NSCLC): a pharmacogenomic study of metabolic enzymes and transporters. Pharm J 17(4):325\u2013330","journal-title":"Pharm J"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-020-02897-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-020-02897-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-020-02897-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T23:17:27Z","timestamp":1621639047000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-020-02897-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,22]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["2897"],"URL":"https:\/\/doi.org\/10.1007\/s00228-020-02897-x","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,22]]},"assertion":[{"value":"20 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in five studies involving human participants were in accordance with the ethical standards of the relevant ethics committees, which approved the studies, and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The requirement for obtaining informed consent was waived due to the retrospective nature of this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}